Propofol infusion syndrome: A rare complication with potentially fatal results

Critical Care Nurse

Volumn 28, Issue 3, 2008, Pages 18-25

  Zaccheo, Melissa M ^a   Bucher, Donald H ^b  

^a HAMOT MEDICAL CENTER   (United States)

^b Hamot Medical Centre   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTRAVENOUS ANESTHETIC AGENT; PROPOFOL;

ACIDOSIS; ACUTE KIDNEY FAILURE; ADULT; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; FATALITY; FEMALE; HEART ARRHYTHMIA; HEPATOMEGALY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; RARE DISEASE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SYNDROME;

ACIDOSIS; ADULT; ANESTHETICS, INTRAVENOUS; ARRHYTHMIAS, CARDIAC; CRITICAL CARE; DRUG MONITORING; FATAL OUTCOME; FEMALE; HEPATOMEGALY; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; NURSE'S ROLE; NURSING ASSESSMENT; PROPOFOL; RARE DISEASES; RHABDOMYOLYSIS; RISK FACTORS; SYNDROME;

EID: 50349099199     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des. 2004;10(29):3639-3649.
2. AstraZeneca. Core data sheet, DIPRIVAN 10 mg/mL (1%) and 20 mg/mL (2%) emulsion for injection or infusion. http://www.anaesthesia-az.com/sites/156/imagebank/typearticleparam509637/CDS+Diprivan.pdf. Created November 2006. Accessed March 5, 2008.
3. AstraZeneca. DIPRIVAN (propofol) injectable emulsion. No. 30193-00. http://www.astrazeneca-us.com/pi/diprivan.pdf. Created November 2006. Accessed March 5, 2008.
4. Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992;305(6854):613-616.
5. Corbett SM, Moore J, Rebuck JA, Rogers FB, Greene CM. Survival of propofol infusion syndrome in a head-injured patient. Crit Care Med. 2006;34(9):2479-2483.
6. McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs. 2003;17(4):235-272.
7. Crozier TA. The 'propofol infusion syndrome': myth or menace? Eur J Anaesthesiol. 2006;23(12):987-989.
8. Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007;62(7):690-701.
9. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29(9): 1417-1425.
10. Vernooy K, Delhaas T, Cremer OL, et al. Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm. 2006;3(2):131-137.
11. Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother. 2002;36(9):1453-1456.
12. Kumar MA, Urrutia VC, Thomas CE, Abou-Khaled KJ, Schwartzman RJ. The syndrome of irreversible acidosis after prolonged propofol infusion. Neurocrit Care. 2005; 3(3):257-259.
13. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119-141.